Kodiak Sciences - KOD EV/Sales Multiple

kodiak.com (KOD) - corporate logo

Kodiak Sciences Inc. (KOD) develops long-acting retinal treatments via the ABC platform. The EV/Sales ratio trajectory on the GURU.Markets chart indicates that the 0.00 mark serves as a key metric. The company plans to generate revenue from the commercialization of tarcocimab tedromer for macular degeneration. However, the absence of current sales and future price competition limit the company's pricing power.

KOD Kodiak Corp Company Value to Revenue (11/23/2025 - 11/20/2026)

Kodiak Corp - analytical breakdowns and key metrics (KOD)

- cash and cash flow indicators:
Fundamental company valuation:KOD (Kodiak Sciences Inc.)
Original product of Kodiak Pharma

Defensive asset screening requires an analysis of business value relative to revenue, excluding debt load. This metric compares market capitalization and net debt against annual turnover to determine the price per unit of sales. For Kodiak Sciences Inc. (KOD) during a period of risky clinical trials, this metric reflects a speculative valuation of future successes. The EV/Sales ratio here captures market optimism or skepticism regarding the commercialization of drugs.